GlaxoSmithKline (GSK) has acquired a Switzerland-based vaccines company, Okairos, for €250m in cash to boost its existing vaccine platform technology expertise and to continue developing the next generation of vaccines. Under the ...
Tags: Glaxosmithkline, Vaccines Business
Biopharmaceutical company Pfizer has decided to discontinue the development of filibuvir, an experimental hepatitis C drug, following a strategic review and capital allocation. The drug, which is in mid-stage clinical testing, is facing ...
Tags: Pfizer, filibuvir drug, drug
US-based biopharmaceutical company Spring Bank Pharmaceuticals has closed a $10.5m Series A financing round from Brock Securities with Gilford Securities as a participator. The firm is planning to invest the fund in its Phase I clinical ...
bioMérieux has recently launched the new CE-marked VIDAS® Anti-HCV test for the detection of antibodies to the hepatitis C virus (HCV), extending the Company’s current product range to provide a complete test menu for ...
Tags: Anti HCV Test, Viral Hepatitis, immunoassay platform, fluorescent assay
The adverse side effects of some medications for hepatitis C can now be observed and studied in laboratory conditions, using petri dishes and test tubes, thanks to the development of a new method by US researchers. A team led by Craig ...
Tags: anti-HCV treatments, hepatitis, disease, PLOS Pathogens
GlaxoSmithKline (GSK), Ligand Pharmaceuticals' partner, has gained FDA priority review status for the supplemental new drug application for Promacta to treat thrombocytopenia in adult patients with chronic hepatitis C virus infection. ...
Tags: GlaxoSmithKline, GSK, promacta, thrombocytopenia
Ansell, a developer of surgical products, has introduced GAMMEX non-latex antimicrobial surgical glove in Canada. The non-latex surgical glove is coated with antimicrobial chlorhexidine gluconate (CHG), which shows effectiveness against ...
Tags: surgical glove
Ligand Pharmaceuticals partner GlaxoSmithKline has submitted regulatory applications in the US and European Union for the use of eltrombopag (Promacta/Revolade) to increase platelet counts in patients with hepatitis C. A supplemental ...